Liehr R M, Reidelberger R D, Rosewicz S, Bussjaeger L J, Solomon T E
Department of Medicine, Kansas University Medical Center, Kansas City.
Regul Pept. 1992 Apr 9;38(3):207-19. doi: 10.1016/0167-0115(92)90103-2.
We examined the role of CCK in bombesin-induced pancreatic growth in rats using the CCK receptor antagonist L-364,718. Rats (155 +/- 1 g, 8-10 per group) received subcutaneous injections every 8 h for 5 days with bombesin (0.6, 1.7 and 5 nmol/kg) or bombesin in combination with L-364,718 (1 mg/kg). After 5 days the pancreas was removed and pancreatic weight, protein content, DNA, amylase and chymotrypsin contents were determined. Bombesin produced a significant increase (48-475%) of pancreatic weight, tissue contents of protein, DNA, amylase and chymotrypsinogen (F = 82, P less than 0.001). When a large dose of bombesin (5 nmol/kg) was combined with L-364,718 a significant inhibition (up to 70%) of all tissue parameters was observed (P less than 0.001). L-364,718 did not affect the growth response to a small dose of bombesin (0.6 nmol/kg). Plasma CCK levels 15 min after a single injection of bombesin (0.6, 1.7 and 5 nmol/kg) were significantly increased in response to the 5 nmol/kg dose (2.0 +/- 0.7 to 3.4 +/- 0.8 pM, F = 6.9, P less than 0.01). No increases of CCK plasma levels were found in response to the 0.6 and 1.7 nmol/kg doses of bombesin, corresponding to the lack of effects of L-364,718 on growth parameters at these doses. Measuring the time-course of CCK plasma levels after a single injection of 5 nmol/kg bombesin revealed an increase from basal values of 1.4 +/- 0.3 pM to maximal levels of 3.5 +/- 0.5 pM after 15 min (F = 7.1, P less than 0.001). Values returned to basal after 60 min. These results suggest that low doses of bombesin act directly at the acinar cell or through release of non-CCK growth factors whereas high doses of bombesin act in part through CCK release.
我们使用胆囊收缩素(CCK)受体拮抗剂L-364,718研究了CCK在蛙皮素诱导的大鼠胰腺生长中的作用。大鼠(体重155±1 g,每组8 - 10只)每8小时皮下注射一次,共注射5天,注射物为蛙皮素(0.6、1.7和5 nmol/kg)或蛙皮素与L-364,718(1 mg/kg)的组合。5天后取出胰腺,测定胰腺重量、蛋白质含量、DNA、淀粉酶和胰凝乳蛋白酶含量。蛙皮素使胰腺重量、蛋白质、DNA、淀粉酶和胰凝乳蛋白酶原的组织含量显著增加(48 - 475%)(F = 82,P < 0.001)。当大剂量蛙皮素(5 nmol/kg)与L-364,718联合使用时,所有组织参数均出现显著抑制(高达70%)(P < 0.001)。L-364,718对小剂量蛙皮素(0.6 nmol/kg)诱导的生长反应没有影响。单次注射蛙皮素(0.6、1.7和5 nmol/kg)15分钟后,血浆CCK水平仅在5 nmol/kg剂量时显著升高(从2.0±0.7升高至3.4±0.8 pM,F = 6.9,P < 0.01)。对于0.6和1.7 nmol/kg剂量的蛙皮素,未发现血浆CCK水平升高,这与L-364,718在这些剂量下对生长参数无影响相对应。测量单次注射5 nmol/kg蛙皮素后血浆CCK水平的时间进程发现,其从基础值1.4±0.3 pM在15分钟后升高至最大值3.5±0.5 pM(F = 7.1,P < 0.001)。60分钟后值恢复至基础水平。这些结果表明,低剂量蛙皮素直接作用于腺泡细胞或通过释放非CCK生长因子起作用,而高剂量蛙皮素部分通过CCK释放起作用。